Detalles de la búsqueda
1.
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol
; 198(3): 535-544, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35438802
2.
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Clin Exp Med
; 23(3): 803-813, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953763
3.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Leukemia
; 36(11): 2739-2742, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36104395
4.
Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.
Leuk Lymphoma
; 53(2): 336-7, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21823831
Resultados
1 -
4
de 4
1
Próxima >
>>